The Latest Breaking News from Vertex

The Dow Jones Industrial Average sold off Tuesday, as Target dived after warning profits would drop in the current quarter.

Dow Jones futures were lower after Monday's stock market action. The 10-year Treasury yield jumped back above 3%.

'The lives of our children are at stake here, and we need to have this drug'

Vertex Pharmaceuticals got an upgrade Wednesday on its burgeoning non-cystic fibrosis pipeline — as VRTX stock inched higher.

Drug stock Vertex is rounding out a new base and nearing a buy point as it continues to deliver solid earnings growth.

Analysts have provided the following ratings for Vertex (NASDAQ:VERX) within the last quarter:

"The lives of our children are being put at risk because of a financial dispute"

Multi-decade-high inflation and aggressive Fed rate increases might push the economy into a recession. So, investors looking to mitigate a market downturn should invest in Dollar Tree (DLTR) and Vertex Pharmaceuticals (VRTX), as they could deliver stable returns because their businesses enjoy a near-inelastic demand.

Vertex Energy Inc (NASDAQ:VTNR) reported first-quarter revenue growth of 60.6% year-over-year to $40.22 million, missing the consensus of $51.69 million. EPS loss was $(0.08) compared to $0.01 a year ago. The gross margin contracted by 466 bps to 3.8%. Vertex's operating loss increased to $(7.27) million from $(0.76) million a year ago.…

  Vertex (NASDAQ:VERX) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

The Dow Jones Industrial Average dropped Friday morning after the key April jobs report. The 10-year Treasury yield hit a new high.